Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 18 - Number 2
Biography
Editorial
Review Article
Oncolytic Viruses: The Best is Yet to Come
, 18(2): 109 - 123Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei and John C. Bell*
DOI: 10.2174/1568009617666170206111609
Review Article
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
, 18(2): 124 - 138Vincenzo Cerullo*, Cristian Capasso, Markus Vaha-Koskela, Otto Hemminki and Akseli Hemminki*
DOI: 10.2174/1568009617666170502152352
Review Article
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
, 18(2): 139 - 152JinWoo Hong and Chae-Ok Yun*
DOI: 10.2174/1568009617666170222123406
Review Article
The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
, 18(2): 153 - 161Mizuho Sato-Dahlman and Masato Yamamoto*
DOI: 10.2174/1568009617666170222123925
Review Article
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
, 18(2): 162 - 170Hiroaki Uchida*, Hirofumi Hamada, Kenji Nakano, Heechung Kwon, Hideaki Tahara, Justus B. Cohen and Joseph C. Glorioso
DOI: 10.2174/1568009617666170206105855
Review Article
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
, 18(2): 177 - 187Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell and Evanthia Galanis*
DOI: 10.2174/1568009617666170222125035
Review Article
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
, 18(2): 188 - 201Takeshi Yamada, Yukako Hamano, Naoyuki Hasegawa, Emiko Seo, Kuniaki Fukuda, Kazunari K. Yokoyama*, Ichinosuke Hyodo and Masato Abei*
DOI: 10.2174/1568009617666170330123841
Review Article
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
, 18(2): 202 - 208Teruhide Yamaguchi* and Eriko Uchida
DOI: 10.2174/1568009617666170222142650
Research Article
TGF-β1 Causes EMT by Regulating N-Acetyl Glucosaminyl Transferases via Downregulation of Non Muscle Myosin II-A through JNK/P38/PI3K Pathway in Lung Cancer
, 18(2): 209 - 219Ghulam Jilany Khan, Yingsheng Gao, Ming Gu, Lai Wang, Sara Khan, Farah Naeem, Herve Semukunzi, Debmalya Roy, Shengtao Yuan* and Li Sun*
DOI: 10.2174/1568009617666170807120304
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Webmaster Contact: info@benthamscience.net